NeuroPace (NPCE) Expected to Announce Earnings on Tuesday

Key Points

• NeuroPace is set to announce its Q2 2025 earnings on August 12th, with analysts predicting a loss of $0.24 per share and $23.08 million in revenue.
• In its last earnings report, NeuroPace exceeded expectations with a reported loss of $0.21 per share and revenue of $22.52 million, compared to analysts' estimates of $0.26 loss and $21.85 million revenue.
• Analysts currently have a consensus rating of "Buy" for NeuroPace stock, with target prices ranging from $16.00 to $18.00 according to recent research reports.

NeuroPace (NASDAQ:NPCE - Get Free Report) is expected to be announcing its Q2 2025 earnings results after the market closes on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.24) per share and revenue of $23.08 million for the quarter. NeuroPace has set its FY 2025 guidance at EPS.

NeuroPace (NASDAQ:NPCE - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.05. NeuroPace had a negative return on equity of 190.84% and a negative net margin of 29.42%. The firm had revenue of $22.52 million during the quarter, compared to the consensus estimate of $21.85 million. On average, analysts expect NeuroPace to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NeuroPace Stock Up 1.4%

NPCE traded up $0.13 on Thursday, hitting $9.02. The company had a trading volume of 32,477 shares, compared to its average volume of 277,264. The stock has a fifty day moving average price of $10.50 and a 200-day moving average price of $11.97. NeuroPace has a 12-month low of $5.45 and a 12-month high of $18.98. The company has a debt-to-equity ratio of 2.46, a quick ratio of 5.70 and a current ratio of 6.63. The stock has a market capitalization of $295.72 million, a price-to-earnings ratio of -10.74 and a beta of 1.89.

Insider Buying and Selling

In related news, major shareholder Orbimed Advisors Llc sold 168,136 shares of the company's stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $15.85, for a total value of $2,664,955.60. Following the sale, the insider owned 3,238,199 shares in the company, valued at $51,325,454.15. This represents a 4.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 20.50% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Cantor Fitzgerald reiterated an "overweight" rating and issued a $17.00 target price on shares of NeuroPace in a research note on Wednesday, May 14th. JPMorgan Chase & Co. lifted their target price on NeuroPace from $14.00 to $16.00 and gave the company an "overweight" rating in a research note on Wednesday, May 14th. Finally, HC Wainwright assumed coverage on NeuroPace in a research note on Wednesday, May 28th. They issued a "buy" rating and a $18.00 target price on the stock. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, NeuroPace presently has a consensus rating of "Buy" and a consensus target price of $17.00.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.